Beam Therapeutics (BEAM) Stock Forecast, Price Target & Predictions
BEAM Stock Forecast
Beam Therapeutics stock forecast is as follows: an average price target of $64.20 (represents a 163.66% upside from BEAM’s last price of $24.35) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BEAM Price Target
The average price target for Beam Therapeutics (BEAM) is $64.20 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $69.00 to $62.00. This represents a potential 163.66% upside from BEAM's last price of $24.35.
BEAM Analyst Ratings
According to 5 Wall Street analysts, Beam Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BEAM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Beam Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Benjamin Burnett | Stifel Nicolaus | $69.00 | $23.34 | 195.69% | 183.37% |
| Feb 01, 2023 | - | Cantor Fitzgerald | $62.00 | $43.45 | 42.69% | 154.62% |
| Dec 20, 2022 | Kostas Biliouris | BMO Capital | $66.00 | $41.59 | 58.69% | 171.05% |
| Dec 13, 2022 | - | Citigroup | $62.00 | $48.19 | 28.66% | 154.62% |
| Apr 28, 2022 | - | Credit Suisse | $62.00 | $39.83 | 55.66% | 154.62% |
The latest Beam Therapeutics stock forecast, released on Sep 11, 2024 by Benjamin Burnett from Stifel Nicolaus, set a price target of $69.00, which represents a 195.69% increase from the stock price at the time of the forecast ($23.34), and a 183.37% increase from BEAM last price ($24.35).
Beam Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $69.00 | $69.00 |
| Last Closing Price | $24.35 | $24.35 | $24.35 |
| Upside/Downside | -100.00% | 183.37% | 183.37% |
In the current month, the average price target of Beam Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Beam Therapeutics's last price of $24.35. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Aug 22, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jul 23, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 02, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 27, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Mar 27, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 05, 2023 | William Blair | Outperform | Outperform | Hold |
| Aug 09, 2023 | Credit Suisse | Neutral | Neutral | Hold |
| Feb 01, 2023 | Cantor Fitzgerald | - | Overweight | Initialise |
| Dec 20, 2022 | BMO Capital | Market Perform | Outperform | Upgrade |
Beam Therapeutics's last stock rating was published by H.C. Wainwright on Sep 11, 2024. The company gave BEAM a "Underperform" rating, the same as its previous rate.
Beam Therapeutics Financial Forecast
Beam Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $17.19M | $20.12M | $24.21M | $20.04M | $15.80M | $16.65M | $8.43M | $51.07M | $763.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K |
| Avg Forecast | $39.75M | $35.20M | $31.17M | $27.59M | $14.83M | $14.83M | $14.67M | $14.67M | $15.17M | $14.68M | $14.18M | $17.09M | $18.67M | $17.09M | $17.32M | $15.61M | $12.71M | $7.15M | $8.39M | $44.14M | $8.56M | $1.07M | $8.34M | $2.00K | $2.00K | $1.50K | $2.00K | $4.51K |
| High Forecast | $39.75M | $35.20M | $31.17M | $27.59M | $14.83M | $14.83M | $14.67M | $14.67M | $15.17M | $27.58M | $14.18M | $17.09M | $27.59M | $17.28M | $17.32M | $15.61M | $12.71M | $7.15M | $8.39M | $44.14M | $8.56M | $1.07M | $8.34M | $2.00K | $2.00K | $1.50K | $2.00K | $5.41K |
| Low Forecast | $39.75M | $35.20M | $31.17M | $27.59M | $14.83M | $14.83M | $14.67M | $14.67M | $15.17M | $4.94M | $14.18M | $17.09M | $13.24M | $16.90M | $17.32M | $15.61M | $12.71M | $7.15M | $8.39M | $44.14M | $8.56M | $1.07M | $8.34M | $2.00K | $2.00K | $1.50K | $2.00K | $3.61K |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 14 | 8 | 9 | 15 | 10 | 16 | 8 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.16% | 1.55% | 1.58% | 2.21% | 1.98% | 0.19% | 5.96% | 0.71% | 0.00% | 3.00% | 3.00% | 4.00% | 3.00% | 1.33% |
Beam Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $18.67M, with a low forecast of $13.24M, and a high forecast of $27.59M. BEAM's average Quarter revenue forecast represents a 8.61% increase compared to the company's last Quarter revenue of $17.19M (Sep 23).
Beam Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 14 | 8 | 9 | 15 | 10 | 16 | 8 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-107.75M | $-109.57M | $-91.44M | $-133.01M | $-95.96M | $-89.92M | $-79.28M | $-62.07M | $-26.37M | $-74.58M | $-200.16M | $-94.19M | $-33.23M | $-33.07M | $-29.36M |
| Avg Forecast | $-35.10M | $-31.08M | $-27.51M | $-24.36M | $-13.10M | $-13.10M | $-12.95M | $-12.95M | $-13.39M | $-12.96M | $-12.51M | $-70.45M | $-16.49M | $-15.09M | $-15.29M | $-75.35M | $-11.22M | $-6.31M | $-7.41M | $-80.58M | $-7.56M | $-947.08K | $-7.36M | $-455.23M | $-1.76K | $-1.32K | $-1.76K | $-19.66M |
| High Forecast | $-35.10M | $-31.08M | $-27.51M | $-24.36M | $-13.10M | $-13.10M | $-12.95M | $-12.95M | $-13.39M | $-4.36M | $-12.51M | $-56.36M | $-11.69M | $-14.92M | $-15.29M | $-60.28M | $-11.22M | $-6.31M | $-7.41M | $-64.47M | $-7.56M | $-947.08K | $-7.36M | $-364.19M | $-1.76K | $-1.32K | $-1.76K | $-15.73M |
| Low Forecast | $-35.10M | $-31.08M | $-27.51M | $-24.36M | $-13.10M | $-13.10M | $-12.95M | $-12.95M | $-13.39M | $-24.35M | $-12.51M | $-84.54M | $-24.36M | $-15.26M | $-15.29M | $-90.41M | $-11.22M | $-6.31M | $-7.41M | $-96.70M | $-7.56M | $-947.08K | $-7.36M | $-546.28M | $-1.76K | $-1.32K | $-1.76K | $-23.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.14% | 7.17% | 1.21% | 11.85% | 15.20% | 12.14% | 0.98% | 8.21% | 27.84% | 10.14% | 0.44% | 53366.57% | 25101.21% | 18738.24% | 1.49% |
undefined analysts predict BEAM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Beam Therapeutics's previous annual EBITDA (undefined) of $NaN.
Beam Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 14 | 8 | 9 | 15 | 10 | 16 | 8 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-96.09M | $-82.78M | $-84.03M | $-38.35M | $-109.58M | $-48.50M | $-55.19M | $-64.71M | $-28.12M | $-76.25M | $-201.56M | $-95.46M | $-34.45M | $-34.22M | $-30.46M |
| Avg Forecast | $-117.95M | $-118.02M | $-115.14M | $-115.20M | $-92.74M | $-92.28M | $-93.93M | $-93.79M | $-100.90M | $-97.83M | $-92.77M | $-74.72M | $-56.89M | $-109.36M | $-117.26M | $-79.91M | $-111.72M | $-104.06M | $-92.22M | $-85.47M | $-78.03M | $-59.64M | $-52.32M | $-458.41M | $-54.56M | $-44.94M | $-42.47M | $-20.40M |
| High Forecast | $-117.95M | $-118.02M | $-115.14M | $-115.20M | $-92.74M | $-92.28M | $-93.93M | $-93.79M | $-100.90M | $-81.38M | $-92.77M | $-59.78M | $-32.65M | $-109.36M | $-117.26M | $-63.93M | $-111.72M | $-104.06M | $-92.22M | $-68.38M | $-78.03M | $-59.64M | $-52.32M | $-366.73M | $-54.56M | $-44.94M | $-42.47M | $-16.32M |
| Low Forecast | $-117.95M | $-118.02M | $-115.14M | $-115.20M | $-92.74M | $-92.28M | $-93.93M | $-93.79M | $-100.90M | $-115.14M | $-92.77M | $-89.66M | $-72.23M | $-109.36M | $-117.26M | $-95.90M | $-111.72M | $-104.06M | $-92.22M | $-102.56M | $-78.03M | $-59.64M | $-52.32M | $-550.10M | $-54.56M | $-44.94M | $-42.47M | $-24.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.71% | 1.05% | 0.34% | 1.05% | 0.53% | 0.65% | 0.83% | 0.47% | 1.46% | 0.44% | 1.75% | 0.77% | 0.81% | 1.49% |
Beam Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BEAM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Beam Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 14 | 8 | 9 | 15 | 10 | 16 | 8 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.41M | $24.66M | $23.49M | $22.68M | $21.82M | $24.06M | $19.25M | $17.77M | $15.77M | $13.40M | $10.27M | $8.35M | $7.50M | $6.94M | $6.81M |
| Avg Forecast | $18.91B | $16.74B | $14.82B | $13.12B | $7.06B | $7.06B | $6.98B | $6.98B | $7.22B | $6.98B | $6.74B | $8.13B | $8.88B | $8.13B | $8.24B | $7.42B | $6.05B | $3.40B | $3.99B | $23.77M | $4.07B | $510.24M | $3.96B | $951.27K | $951.27K | $713.45K | $951.27K | $2.15M |
| High Forecast | $18.91B | $16.74B | $14.82B | $13.12B | $7.06B | $7.06B | $6.98B | $6.98B | $7.22B | $13.12B | $6.74B | $8.13B | $13.12B | $8.22B | $8.24B | $7.42B | $6.05B | $3.40B | $3.99B | $28.52M | $4.07B | $510.24M | $3.96B | $951.27K | $951.27K | $713.45K | $951.27K | $2.57M |
| Low Forecast | $18.91B | $16.74B | $14.82B | $13.12B | $7.06B | $7.06B | $6.98B | $6.98B | $7.22B | $2.35B | $6.74B | $8.13B | $6.30B | $8.04B | $8.24B | $7.42B | $6.05B | $3.40B | $3.99B | $19.01M | $4.07B | $510.24M | $3.96B | $951.27K | $951.27K | $713.45K | $951.27K | $1.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.81% | 0.00% | 0.03% | 0.00% | 10.80% | 8.78% | 10.52% | 7.29% | 3.18% |
Beam Therapeutics's average Quarter SG&A projection for Dec 23 is $8.88B, based on 8 Wall Street analysts, with a range of $6.30B to $13.12B. The forecast indicates a 34852.57% rise compared to BEAM last annual SG&A of $25.41M (Sep 23).
Beam Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 14 | 8 | 9 | 15 | 10 | 16 | 8 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.22 | $-1.08 | $-1.16 | $-0.54 | $-1.56 | $-0.69 | $-0.80 | $-0.95 | $-0.42 | $-1.23 | $-3.35 | $-1.59 | $-0.69 | $-0.69 | $-1.03 |
| Avg Forecast | $-1.43 | $-1.43 | $-1.40 | $-1.40 | $-1.13 | $-1.12 | $-1.14 | $-1.14 | $-1.23 | $-1.19 | $-1.13 | $-1.42 | $-0.69 | $-1.33 | $-1.42 | $-1.32 | $-1.36 | $-1.26 | $-1.12 | $-0.89 | $-0.95 | $-0.72 | $-0.64 | $-0.74 | $-0.66 | $-0.55 | $-0.52 | $-0.51 |
| High Forecast | $-1.43 | $-1.43 | $-1.40 | $-1.40 | $-1.13 | $-1.12 | $-1.14 | $-1.14 | $-1.23 | $-0.99 | $-1.13 | $-1.42 | $-0.40 | $-1.33 | $-1.42 | $-1.32 | $-1.36 | $-1.26 | $-1.12 | $-0.89 | $-0.95 | $-0.72 | $-0.64 | $-0.74 | $-0.66 | $-0.55 | $-0.52 | $-0.51 |
| Low Forecast | $-1.43 | $-1.43 | $-1.40 | $-1.40 | $-1.13 | $-1.12 | $-1.14 | $-1.14 | $-1.23 | $-1.40 | $-1.13 | $-1.42 | $-0.88 | $-1.33 | $-1.42 | $-1.32 | $-1.36 | $-1.26 | $-1.12 | $-0.89 | $-0.95 | $-0.72 | $-0.64 | $-0.74 | $-0.66 | $-0.55 | $-0.52 | $-0.51 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.76% | 0.88% | 0.40% | 1.23% | 0.62% | 0.90% | 1.00% | 0.58% | 1.94% | 4.53% | 2.39% | 1.26% | 1.34% | 2.04% |
According to undefined Wall Street analysts, Beam Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BEAM previous annual EPS of $NaN (undefined).
Beam Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $3.22 | $39.75 | 1134.47% | Buy |
| NTLA | Intellia Therapeutics | $20.98 | $119.16 | 467.97% | Buy |
| EDIT | Editas Medicine | $3.31 | $17.00 | 413.60% | Buy |
| PRME | Prime Medicine | $3.80 | $17.25 | 353.95% | Buy |
| VERV | Verve Therapeutics | $5.46 | $21.50 | 293.77% | Buy |
| SANA | Sana Bio | $4.06 | $12.00 | 195.57% | Buy |
| BEAM | Beam Therapeutics | $24.35 | $64.20 | 163.66% | Buy |
| CRSP | CRISPR Therapeutics | $48.29 | $109.58 | 126.92% | Buy |
| CRBU | Caribou Biosciences | $1.94 | $3.00 | 54.64% | Buy |
| DNA | Ginkgo Bioworks | $8.38 | $7.34 | -12.41% | Buy |
| VRTX | Vertex Pharmaceuticals | $498.73 | $393.86 | -21.03% | Buy |
BEAM Forecast FAQ
Is Beam Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Beam Therapeutics (BEAM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of BEAM's total ratings.
What is BEAM's price target?
Beam Therapeutics (BEAM) average price target is $64.2 with a range of $62 to $69, implying a 163.66% from its last price of $24.35. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Beam Therapeutics stock go up soon?
According to Wall Street analysts' prediction for BEAM stock, the company can go up by 163.66% (from the last price of $24.35 to the average price target of $64.2), up by 183.37% based on the highest stock price target, and up by 154.62% based on the lowest stock price target.
Can Beam Therapeutics stock reach $40?
BEAM's average twelve months analyst stock price target of $64.2 supports the claim that Beam Therapeutics can reach $40 in the near future.
What are Beam Therapeutics's analysts' financial forecasts?
Beam Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $59M (high $59M, low $59M), average EBITDA is $-52.088M (high $-52.088M, low $-52.088M), average net income is $-373M (high $-373M, low $-373M), average SG&A $28.06B (high $28.06B, low $28.06B), and average EPS is $-4.528 (high $-4.528, low $-4.528). BEAM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $133.71M (high $133.71M, low $133.71M), average EBITDA is $-118M (high $-118M, low $-118M), average net income is $-466M (high $-466M, low $-466M), average SG&A $63.6B (high $63.6B, low $63.6B), and average EPS is $-5.665 (high $-5.665, low $-5.665).
Did the BEAM's actual financial results beat the analysts' financial forecasts?
Based on Beam Therapeutics's last annual report (Dec 2022), the company's revenue was $60.92M, which missed the average analysts forecast of $72.4M by -15.85%. Apple's EBITDA was $-401M, beating the average prediction of $-106M by 280.45%. The company's net income was $-264M, missing the average estimation of $-393M by -33.01%. Apple's SG&A was $87.8M, missing the average forecast of $13.46B by -99.35%. Lastly, the company's EPS was $-3.76, missing the average prediction of $-4.633 by -18.85%. In terms of the last quarterly report (Sep 2023), Beam Therapeutics's revenue was $17.19M, beating the average analysts' forecast of $17.09M by 0.61%. The company's EBITDA was $-108M, beating the average prediction of $-15.086M by 614.21%. Beam Therapeutics's net income was $-96.088M, missing the average estimation of $-109M by -12.14%. The company's SG&A was $25.41M, missing the average forecast of $8.13B by -99.69%. Lastly, the company's EPS was $-1.22, missing the average prediction of $-1.329 by -8.18%